Please assess the completion status of the following clinical trial:

Trial Title: FDG-PET/CT Scans in Patients With Stage IIIB or Stage IV NSCLC Undergoing Chemotherapy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed non-small cell lung cancer~  * Newly diagnosed stage IIIB (with malignant pleural effusion) or stage IV disease (Group I and II), or newly diagnosed stage IIIA, IIIB, or IV (Group III) determined by all of the following:~    * CT scan or MRI of the chest and upper abdomen (including liver and adrenal glands) within the past 4 weeks~   * History/physical examination within the past 6 weeks~   * CT scan or MRI of the brain within the past 4 weeks, if there is headache, mental/physical impairment, or other signs or symptoms suggesting brain metastases within the past 2 months~ * No small cell carcinoma~ * No pure bronchioloalveolar carcinoma~* Patients with recurrent or metastatic disease are eligible provided they meet 1 of the following criteria:~  * Received surgery or radiotherapy for treatment of the primary tumor and locoregional disease ≥ 3 months prior to study entry AND have a measurable lesion in the chest~ * Received chemotherapy in the adjuvant setting or as part of combined modality therapy for locoregional disease ≥ 3 months prior to recurrent or metastatic disease diagnosis AND have a measurable lesion in the chest~* Measurable disease, defined as at least 1 measurable primary tumor or other intrathoracic/supraclavicular lesion ≥ 2 cm~* Scheduled to be treated with a platinum-based dual-agent chemotherapy regimen administered at 3-week intervals with or without bevacizumab or cetuximab (Group I and II)~* Scheduled to be treated with standard chemotherapy in the current protocol, other standard chemotherapy, experimental chemotherapy, or other treatment including no treatment (Group III)~* No symptomatic brain metastases (Groups I and II only)~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2 (Groups I and II only)~  * Group III may include potential participants regardless of ECOG performance status score~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* Able to tolerate positron emission tomography (PET)/CT scanning~* No contraindication to chemotherapy and PET/CT scanning, as demonstrated by laboratory testing~* No poorly controlled diabetes (i.e., fasting glucose level \> 150 mg/dL) despite attempts to improve glucose control by fasting duration and adjustment of medications~* No prior malignancy other than basal cell or squamous cell carcinoma of the skin, carcinoma in situ, or other cancer from which the patient has been disease free for ≥ 3 years (Groups I and II)~  * Prior malignancy is not an exclusion factor for Group III~* No clinical or radiographic signs of post-obstructive pneumonia~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* More than 3 months since prior thoracic radiotherapy, lung surgery, or chemotherapy~* Prior chemotherapy in the adjuvant setting or as part of a combined modality regimen for locoregional disease that was given ≥ 3 months prior to diagnosis of recurrent or metastatic disease allowed~* No planned treatment with any targeted biologic therapy including gefitinib or erlotinib hydrochloride (Group I and II)~* No concurrent chemoradiotherapy~* No concurrent bevacizumab

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group A - 3 FDG-PET/CT Scans (Type: EXPERIMENTAL): Two FDG-PET/CT scans prior to 1st cycle of chemotherapy, plus 2 optional volumetric CT scans. One FDG-PET/CT after 1st cycle of chemotherapy, plus 1 optional volumetric CT scan.
- Group B - 2 FDG-PET/CT + 1 Optional (Type: EXPERIMENTAL): One FDG-PET/CT prior to 1st cycle of chemotherapy; 1 FDG-PET/CT after the 1st cycle of chemotherapy; 1 optional FDG-PET/CT after the 2nd cycle of chemotherapy. All three with optional volumetric CT scans.
- Group C - Test-Retest (Type: EXPERIMENTAL): Test-retest sequence for FDG-PET/CT; two scans with optional volumetric CT to be completed prior to 1st cycle of chemotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues